Alpha Cognition Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $28.99 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Alpha Cognition Inc had its IPO on under the ticker symbol ACOGF.
The company operates in the Healthcare sector and Biotechnology industry. Alpha Cognition Inc has a staff strength of 0 employees.
Shares of Alpha Cognition Inc opened at $0.23 at the start of the last trading session i.e. 2023-03-25.
The stocks traded within a range of $0.23 - $0.23, and closed at $0.23.
This is a 0% increase from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of Alpha Cognition Inc have slipped by -33.07%.
Alpha Cognition Inc's Key Ratios
Alpha Cognition Inc has a market cap of $28.99 million, indicating a price to book ratio of 9.903 and a price to sales ratio of 0.
In the last 12-months Alpha Cognition Inc’s revenue was $0 with a gross profit of $-37504 and an EBITDA of $-13850008. The EBITDA ratio measures Alpha Cognition Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Alpha Cognition Inc’s operating margin was 0% while its return on assets stood at -160.88% with a return of equity of -696.94%.
In Q3, Alpha Cognition Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Alpha Cognition Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.17 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alpha Cognition Inc’s profitability.
Alpha Cognition Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.3712. Its price to sales ratio in the trailing 12-months stood at 0.
Alpha Cognition Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $4.47 million
- Total Liabilities
- $2.30 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Alpha Cognition Inc ended 2023 with $4.47 million in total assets and $0 in total liabilities. Its intangible assets were valued at $4.47 million while shareholder equity stood at $1.77 million.
Alpha Cognition Inc ended 2023 with $0 in deferred long-term liabilities, $2.30 million in other current liabilities, 40258881.00 in common stock, $-45959050.00 in retained earnings and $0 in goodwill. Its cash balance stood at $3.72 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Alpha Cognition Inc’s total current assets stands at $3.82 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $539171.00 and inventory worth $0.
In 2023, Alpha Cognition Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Alpha Cognition Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Alpha Cognition Inc stock is currently trading at $0.23 per share. It touched a 52-week high of $1 and a 52-week low of $1. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.27 and 200-day moving average was $0.36 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 2340.4% of the company’s stock are held by insiders while 1276.5% are held by institutions.
Frequently Asked Questions About Alpha Cognition Inc
Similar Industry Stocks (Biotechnology)
Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.